Merck has announced encouraging Phase 3 results for its investigational cancer therapy sacituzumab tirumotecan (sac-TMT), offering new hope for patients with advanced or recurrent endometrial cancer who have limited treatment options after standard therapies fail.

The company revealed that the global TroFuse-005 clinical trial successfully achieved its two primary goals, improving overall survival (OS) and progression-free survival (PFS), when compared with conventional chemotherapy in previously treated patients.

Novartis announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.

Applications in the prescribed format are invited from eligible candidates for the various post on a purely temporary basis in the ongoing extramural research project funded by Uttar Pradesh State AIDS Control Society, NACO titled “Investigating Tattooing as a Potential Vector for HIV/AIDS in Uttar Pradesh: Body Art to Blood Safety” under Department of Community & Family Medicine, AIIMS Gorakhpur. 

Post : Research assistant (Project Technician Support - III)